BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 25726059)

  • 1. The role of radiation therapy in pancreatic ductal adenocarcinoma in the neoadjuvant and adjuvant settings.
    Franke AJ; Rosati LM; Pawlik TM; Kumar R; Herman JM
    Semin Oncol; 2015 Feb; 42(1):144-62. PubMed ID: 25726059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings.
    Badiyan SN; Molitoris JK; Chuong MD; Regine WF; Kaiser A
    Surg Oncol Clin N Am; 2017 Jul; 26(3):431-453. PubMed ID: 28576181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of chemoradiotherapy in the adjuvant and neoadjuvant settings for resectable pancreatic cancer.
    Sen N; Falk S; Abrams RA
    Clin Oncol (R Coll Radiol); 2014 Sep; 26(9):551-9. PubMed ID: 25024090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of radiation therapy in patients with resectable pancreatic cancer.
    Palta M; Willett C; Czito B
    Oncology (Williston Park); 2011 Jul; 25(8):715-21, 727. PubMed ID: 21874833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation.
    Hoffe S; Rao N; Shridhar R
    Semin Radiat Oncol; 2014 Apr; 24(2):113-25. PubMed ID: 24635868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of radiation therapy in the management of pancreatic cancer.
    Goodman KA; Hajj C
    J Surg Oncol; 2013 Jan; 107(1):86-96. PubMed ID: 22532174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO).
    Brunner TB; Grabenbauer GG; Meyer T; Golcher H; Sauer R; Hohenberger W
    BMC Cancer; 2007 Mar; 7():41. PubMed ID: 17338829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.
    Greer SE; Pipas JM; Sutton JE; Zaki BI; Tsapakos M; Colacchio TA; Gibson JJ; Wiener DC; Ripple GH; Barth RJ
    J Am Coll Surg; 2008 Mar; 206(3):451-7. PubMed ID: 18308215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a role for chemoradiotherapy in the treatment of pancreatic carcinoma?
    Pasetto LM; Jirillo A; Stefani M; Monfardini S
    Anticancer Res; 2003; 23(3C):2805-13. PubMed ID: 12926117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiochemotherapy in the management of pancreatic cancer--part I: neoadjuvant treatment.
    Mornex F; Girard N; Delpero JR; Partensky C
    Semin Radiat Oncol; 2005 Oct; 15(4):226-34. PubMed ID: 16183476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of borderline resectable pancreatic adenocarcinoma.
    Jia Y; Wang TJ; Allendorf J; Saif MW
    JOP; 2012 Mar; 13(2):147-50. PubMed ID: 22406587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
    Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conclusions from the European Study Group for Pancreatic Cancer adjuvant trial of chemoradiotherapy and chemotherapy for pancreatic cancer.
    Ghaneh P; Neoptolemos JP
    Surg Oncol Clin N Am; 2004 Oct; 13(4):567-87, vii-viii. PubMed ID: 15350935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Pancreatic Adenocarcinoma: A Decision Analysis.
    Sharma G; Whang EE; Ruan DT; Ito H
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1229-37. PubMed ID: 26152276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
    Silvestris N; Longo V; Cellini F; Reni M; Bittoni A; Cataldo I; Partelli S; Falconi M; Scarpa A; Brunetti O; Lorusso V; Santini D; Morganti A; Valentini V; Cascinu S
    Crit Rev Oncol Hematol; 2016 Feb; 98():309-24. PubMed ID: 26653573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant therapy for pancreas cancer: past lessons and future therapies.
    Sutton JM; Abbott DE
    World J Gastroenterol; 2014 Nov; 20(42):15564-79. PubMed ID: 25400440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Advances in Localized Pancreatic Cancer.
    Tsai S; Evans DB
    JAMA Surg; 2016 Sep; 151(9):862-8. PubMed ID: 27276001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenocarcinoma of the pancreas: the rationale for neoadjuvant therapy.
    Sperti C; Pasquali C; Pastorelli D; Ferronato A; Decet G; Pedrazzoli S
    Acta Biomed; 2003; 74 Suppl 2():91-5. PubMed ID: 15055044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
    Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
    Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.